Table 1 Characteristics of the eligible studies.
Author | Year | Country | Clinical stage | Arm | Duration (wks) | Num | Age (years), median (rang) | Postmenopausal (n) | HR+/HER2+(n) | Tumor grade (n) | Clinical tumor status (n) | Nodal status (n) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | miss | T0-T2 | T3 | T4 | N0 | N1 | N2-NX | ||||||||||
C.Palmieri | 2014 | UK | T2/ above/any T with nodal ≥ 20mm | CT | 18 | 22 | – | 22 | 22/2 | 0 | 15 | 4 | 3 | – | – | – | – | – | – |
Let | 18–23 | 22 | – | 22 | 22/2 | 1 | 14 | 4 | 3 | – | – | – | – | – | – | ||||
Takashi Hojo | 2013 | Japan | IIA-IIIA | Exe (<20wks) | 16 | 26 | 66 (51–80) | 26 | 26/1 | – | – | – | – | 24 | 2 | 0 | 21 | 5 | 0 |
Exe (≥20wks) | 24 | 26 | 64 (57–80) | 26 | 26/3 | – | – | – | – | 24 | 2 | 0 | 24 | 2 | 0 | ||||
Matthew J.Ellis | 2011 | US | II or III | Exe (<20wks) | 16–18 | 124 | 69 (43–90) | 124 | 124/8 | 35 | 69 | 20 | 0 | 90 | 25 | 9 | 96 | 26 | 2 |
Let | 16–18 | 127 | 65 (49–90) | 127 | 127/13 | 26 | 83 | 1 | 17 | 95 | 24 | 8 | 80 | 41 | 6 | ||||
Ana | 16–18 | 123 | 65 51–87) | 123 | 123/12 | 30 | 73 | 19 | 1 | 94 | 24 | 6 | 01 | 29 | 3 | ||||
Jose´ Baselga | 2009 | Spain | M0 | Eve+Let | 16 | 138 | 69 (46–88) | 138 | 138/– | 10 | 50 | 32 | 46 | 100 | 29 | 9 | 84 | 38 | 9 |
Let | 16 | 132 | 67 (43–84) | 132 | 132/– | 8 | 55 | 20 | 49 | 102 | 20 | 10 | 84 | 36 | 6 | ||||
Louis Wing-Cheong Chow | 2008 | China | NA | Exe (<20wks)+Cel | 12 | 30 | 69 (49–87) | 30 | 30/6 | – | – | – | – | – | – | – | – | – | – |
Exe (<20wks) | 12 | 24 | 67 (48–91) | 24 | 24/2 | – | – | – | – | – | – | – | – | – | – | ||||
Let | 12 | 28 | 75 (49–93) | 28 | 28/2 | – | – | – | – | – | – | – | – | – | – | ||||
Ian E. Smith | 2007 | UK | I-IIIB | Ana+Gef | 16 | 121 | – | 121 | 121/– | 23 | 55 | 14 | 29 | 110 | 11 | 77 | 39 | 5 | |
Ana | 16 | 85 | 70.3 | 85 | 85/– | 18 | 33 | 16 | 18 | 79 | 6 | 49 | 35 | 1 | |||||
Luigi Cataliotti | 2006 | Italy | LABC | Ana | 12 | 228 | 48.7–91.5 | 228 | 228/– | – | – | – | – | – | – | – | – | – | – |
Tam | 12 | 223 | 44.1–95.9 | 223 | 223/– | – | – | – | – | – | – | – | – | – | – | ||||
Ian E. Smith | 2005 | UK | LABC | Ana | 12 | 113 | 73.2(51.8–90.2) | 113 | 113/– | – | – | – | – | – | – | – | – | – | – |
Tam | 12 | 108 | 71.5(49.8–88.4) | 108 | 108/– | – | – | – | – | – | – | – | – | – | – | ||||
Ana+Tam | 12 | 109 | 73.2(51.6–85.7) | 109 | 109/– | – | – | – | – | – | – | – | – | – | – | ||||
W.Eiermann | 2001 | Germany | T2-T4c.N0-N2 | Let | 16 | 154 | 68 | 154 | 154/– | – | – | – | 77 | 42 | 35 | 75 | 68 | 11 | |
Tam | 16 | 170 | 67 | 170 | 166/– | – | – | – | – | 91 | 30 | 49 | 83 | 66 | 21 | ||||
